On September 2, 2022, the Board of Directors of Statera Biopharma, Inc. appointed John Kallassy as a director of the Company, effective September 2, 2022, to fill the vacancy created by Randy Saluck's resignation. Mr. Kallassy will serve in such position until his successor is elected and qualified or until his earlier death, resignation, or removal. Mr. Kallassy will serve as a member of the Board's audit committee, compensation committee, and nominating and corporate governance committee.

The Board has affirmatively determined that Mr. Kallassy is “independent” within the meaning of the listing standards of The Nasdaq Stock Market (“Nasdaq”). In addition, Mr. Kallassy is independent under Nasdaq's heightened independence standards applicable to audit committee and compensation committee members. The Board also appointed Mr. Kallassy as an “audit committee financial expert” as defined in Item 407(d)(5) of Regulation S-K and Chairperson of the Audit Committee of the Board.

Mr. Kallassy currently serves as Chief Executive Officer and Board Chairman of biotech company Bactana Corp. and Chief Financial Officer of animal health biologics company Torigen Pharmaceuticals, Inc. Mr. Kallassy has more than 25 years' experience in finance and biotech innovation, including roles as CEO of Siemens spinoff Zargis Medical Corp. and chief financial officer of Jaguar Health, which he supported through its Nasdaq IPO in 2015.

Mr. Kallassy received his bachelor's degree in biology from the State University of New York at Brockport, studied pharmacology at the University of Leeds, and received his MBA from Cornell's Johnson Graduate School of Management.